Inclusion Criteria:

- Patients with histologically confirmed UPSC at surgical stage 1b to 4 disease. The
serous-papillary component of the specimen must be at least 30 percent. Patients with
surgical stage 1a disease should not be enrolled.

- Females aged >= 18 years old.

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

- Patients may not have received any prior chemotherapy regimens for UPSC.

- Patients must have adequate bone marrow, renal, hepatic and neurologic function.

- Patients must be informed of the investigational nature of the study and sign an
informed consent form.

- Patients with previous malignancy are eligible only if the patient has been
disease-free for >= 5 years.

Exclusion Criteria:

- Patients with pre-existing >= grade 2 neurotoxicity.

- Patients with uncontrolled hypertension, (systolic blood pressure >180 mm Hg or
diastolic blood pressure >100 mm Hg) or uncontrolled cardiac arrhythmia or diabetes
mellitus

- Patients with a history of other malignancy within the last 5 years that could affect
the diagnosis or assessment of UPSC.

- Patients who have a history of serious cardiac disease that is not adequately
controlled are not allowed. Patients with documented myocardial infarction within 6
months preceding study entry; congestive heart failure; unstable angina; a clinically
significant pericardial effusion; or arrhythmias are also ineligible.

- Patients with an active serious infection or other serious underlying medical
condition that would otherwise impair their ability to receive protocol treatment.

- Serious medical or psychiatric illnesses that would prevent informed consent.
Dementia or significantly altered mental status that would prohibit the understanding
and/or giving of informed consent.

- Patients with prior significant allergic reactions to drugs containing cremophor,
such as cyclosporine, or vitamin K are not eligible. A significant reaction may be
defined as, but is not limited to, the description of grade >= 3 allergic reactions
using the Common Toxicity Criteria (CTC). Patients with known hypersensitivity to
paclitaxel, carboplatin or Cremophor EL.

- Patients who have received prior whole pelvis radiotherapy.

- Patients with uncontrolled pelvic inflammatory disease that would contraindicate
pelvic radiotherapy.

- Patients who are pregnant or breast-feeding.

- Patients receiving other investigational therapy.